Bausch + Lomb Corporation is a global eye health company that develops, manufactures, and markets products across three segments: Vision Care (soft and specialty contact lenses and lens care solutions), Surgical (intraocular lenses, cataract and vitreoretinal surgical devices and equipment), and Ophthalmic Pharmaceuticals (prescription and over-the-counter eye drops and ointments). Its portfolio spans polymer-based biomaterials for lenses, sterile solutions, and drug formulations used by eye care professionals and patients worldwide.
Founded in 1853, the company became publicly traded in 2022 following its spin-off from Bausch Health Companies, which remains a significant shareholder. Bausch + Lomb operates in more than 100 countries and supports R&D and manufacturing for ophthalmic devices and formulations, with longstanding roots in North American eye care markets. Ticker: BLCO (NYSE, TSX).
Also known as Bausch & Lomb.
None yet. When a new project in the record names Bausch + Lomb as owner, partner or investor, it shows here.
Brett Icahn joins IFF's Audit and Transaction Committees, while Richard Mulligan joins the Innovation Committee, following a cooperation agreement with Icahn Capital.
